At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Oxytocin Treatment of Alcohol Withdrawal
In Brief
A Phase 1 clinical trial evaluating intranasal oxytocin spray and intranasal spray without oxytocin for Alcohol Withdrawal. Completed, enrolled 14 participants across 2 sites.
Detailed Summary
Purpose: Test whether intranasal administration of the neuropeptide, oxytocin, is effective in decreasing alcohol withdrawal symptoms, the number of bouts of withdrawal requiring standard medication treatment (lorazepam) and the amount of lorazepam required to control withdrawal bouts in individuals undergoing medical detoxification. Also, determine rates of subject recruitment and retention in the inpatient setting. Participants: 80 alcohol dependent patients, 18-65 years of age, admitted for medical detoxification. Procedures (methods): Subjects will be inpatients undergoing medical detoxification from alcohol. Oxytocin or placebo will be administered in a nasal spray twice daily in a randomized, double blind manner for three days. Withdrawal symptoms will be measured routinely at q4 hours and prn for length of hospital stay. Lorazepam will be given whenever withdrawal symptoms increase above specific parameters.
Study Details
Timeline
Interventions
6 insufflations (24 IU of oxytocin total) given twice daily for 3 days
6 insufflations (0.1 metered dose/insufflation) twice daily